Given the rise in newborn screening for ALD since 2019, and the untapped potential of existing genetic research, the Halls ...

X-linked adrenoleukodystrophy (X-ALD) is a debilitating disease caused by mutations in the ABCD1 gene. Approximately 30% of affected boys develop the progressive ...

Unless the two appeal the board’s ruling to judicial review in Lake County Circuit Court, Taylor remains on the ballot, which leaves an interesting scenario for the April municipal election. There ...

It is either tragically funny or devastatingly sad that while a genetic counselor explained the random lunacy of my son’s deadly disease to me all I could think of was how our current situation bears ...

Schwab is facing Gene Decker in the Democratic primary ... Mayor Leon Rockingham Jr. is seeking his sixth term and is running against Ald. Kenneth Smith, 5th Ward, for the Democratic nomination.

It is estimated that around a third of patients with ALD will go on to develop progressive ... of Harvard Medical School. In the US, a gene therapy for cALD from bluebird bio – Skysona (elivaldo ...

Bluebird bio could be just a few months away from approval of its gene therapy for rare disease cerebral adrenoleukodystrophy (CALD) in the EU, after the EMA started an accelerated review.

The candidate targets HSD17B13, a gene that is involved in lipid metabolism ... patients with advanced fibrosis and patients with ALD. The program is emblematic of GSK’s plans for obesity ...

DURECT Corporation today announced the publication of a peer-reviewed article on the AHFIRM trial data in NEJM Evidence. The full article, entitled, "Larsucosterol for the Treatment of ...

Note that for IL-22 and IL-26 putative regulators are provided (Human Gene Database, Weizmann Institute of Science ... As both inflammation and hepatocyte damage are the main reasons for ALD, combined ...

Research analysts at Leerink Partnrs upped their Q4 2024 earnings estimates for shares of bluebird bio in a research report issued on Wednesday, January 22nd. Leerink Partnrs analyst M. Foroohar now ...